e-learning
resources
Vienna 2012
Monday, 03.09.2012
Clinical aspects and treatment of asthma and allergic respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma
K. Matsunaga, A. Hayata, T. Hirano, M. Ichinose (Wakayama, Japan)
Source:
Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Session:
Clinical aspects and treatment of asthma and allergic respiratory diseases
Session type:
Thematic Poster Session
Number:
2345
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Matsunaga, A. Hayata, T. Hirano, M. Ichinose (Wakayama, Japan). Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma. Eur Respir J 2012; 40: Suppl. 56, 2345
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009
The prognostic value of extended lung function characterization in COPD
Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers
Year: 2020
Influence of β2-adrenoceptor genotype on risk of asthma worsening using fluctuation analysis of lung function
Source: Eur Respir J 2007; 30: Suppl. 51, 447s
Year: 2007
Combining exhaled-breath analysis data with clinical parameters to improve the diagnosis of lung cancer
Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer
Year: 2019
Non-invasive inflammatory markers can predict diagnosis, severity and stability of paediatric asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 122s
Year: 2006
Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011
Novel lung function tests can improve phenotyping and differential therapy in COPD
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD
Source: Annual Congress 2008 - Structural remodelling in COPD
Year: 2008
Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020
Consensus network analysis reveals pathways associated with lung function decline in both COPD and IPF
Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis
Year: 2017
The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 327s
Year: 2006
Prognostic assessment in COPD without lung function: the B-AE-D indices
Source: Eur Respir J 2016; 47:1635-1644
Year: 2016
Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019
Role of biomarkers in the assessment and phenotyping asthma and COPD
Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases
Year: 2017
Analysis of spontaneous breathing can predict abnormal lung function in asthma
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021
Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
Source: Eur Respir J, 58 (3) 2004133; 10.1183/13993003.04133-2020
Year: 2021
Novel method of expressing serum biomarkers profiling in COPD patients: The heatmap-clinical pattern profile
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
Clinical relevance of small airways assessment by lung function tests in asthma
Source: International Congress 2018 – Biomarkers and lung function in airway disease
Year: 2018
Cluster analysis identifies distinct clinical phenotypes with poor treatment responsiveness in asthma.
Source: International Congress 2018 – Asthma: clinical screening tools
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept